Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric’s Licensing Deals And More
Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized Anxiety
Psilocybin-assisted therapy has hit a milestone as clinical trial results show potential benefits for Generalized Anxiety Disorder (GAD.)
With variable symptoms, the condition typically involves a person suffering from excessive anxiety and worry for over six months, potentially causing significant distress and impairment in social, occupational or other areas of functioning. A relatively common disorder, successful treatment of GAD remains inadequate, bringing on side effects and high costs.
The new topline clinical outcomes correspond to a Phase 2 study assessing psilocybin therapy’s potential for treatment of Generalized Anxiety Disorder (GAD), conducted by clinical-stage cannabinoid and psychedelics biotech company Incannex Healthcare (NASDAQ:IXHL). Read more.
Beckley Academy’s Open-Source Psychedelic Therapy Learning Framework Is Out: What’s It All About? Authoring Team Shares Insights
The medical psychedelics field is at a pivotal juncture. With MDMA-assisted therapy close to federal legalization for the treatment of PTSD in the U.S. and other psychedelic substances potentially following suit, these therapies are poised to revolutionize treatment for certain mental health issues.
And yet the field has some recognizable and potentially conflictive gaps, such as the absence of national training standards and certifications for those providing the therapies.
To remedy this lack, the educational studio Beckley Academy is moving forward by publishing what’s believed to be the first open-source learning framework to advance psychedelic-assisted therapy (PAT) training standards. Learn more.
EXCLUSIVE: Enveric Biosciences Announces Non-Binding Deals To License Three Types Of Drug Compounds
Enveric Biosciences (NASDAQ:ENVB), a Florida-headquartered biotech company developing novel neuroplasticity-promoting small molecule therapeutics for depression, anxiety and addiction disorders treatment has signed three non-binding term sheets with another (undisclosed) biotechnology company toward the out-licensing of three classes of compounds.
The news comes …